Trials / Recruiting
RecruitingNCT06190886
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- Proviva Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PTX-912 | Investigation Product Monotherapy |
Timeline
- Start date
- 2024-06-11
- Primary completion
- 2026-05-14
- Completion
- 2026-07-24
- First posted
- 2024-01-05
- Last updated
- 2024-11-07
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06190886. Inclusion in this directory is not an endorsement.